In yesterday’s Wall Street session, Day One Biopharmaceuticals Inc (NASDAQ:DAWN) shares traded at $15.19, down -8.71% from the previous session.
DAWN stock price is now -0.25% away from the 50-day moving average and 12.32% away from the 200-day moving average. The market capitalization of the company currently stands at $1.33B.
With the price target enhanced from $30 to $33, Needham maintained Buy rating for Day One Biopharmaceuticals Inc (NASDAQ: DAWN). On April 25, 2023, BofA Securities Downgraded its previous ‘Buy’ rating to ‘Underperform’ on the stock reducing its target price from $34 to quote $9, while ‘CapitalOne’ rates the stock as ‘Overweight’
In other news, Blackman Samuel C., HEAD OF R&D sold 10,000 shares of the company’s stock on Apr 18 ’24. The stock was sold for $160,163 at an average price of $16.02. Upon completion of the transaction, the HEAD OF R&D now directly owns 1,174,662 shares in the company, valued at $17.84 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 25 ’24, HEAD OF R&D Blackman Samuel C. sold 10,000 shares of the business’s stock. A total of $160,055 was realized by selling the stock at an average price of $16.01. This leaves the insider owning 1,184,662 shares of the company worth $18.0 million. A total of 32.55% of the company’s stock is owned by insiders.
During the past 12 months, Day One Biopharmaceuticals Inc has had a low of $9.67 and a high of $17.85. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 12.72, and a quick ratio of 12.72.
Day One Biopharmaceuticals Inc(DAWN) Company Profile
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.
